|

Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis

RECRUITINGSponsored by University Hospital, Basel, Switzerland
Actively Recruiting
SponsorUniversity Hospital, Basel, Switzerland
Started2018-09-04
Est. completion2028-12
Eligibility
Age18 Years – 80 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05177523

Summary

This project is to: 1. Quantify differences in axonal integrity and organization in aMS versus naPMS patients. 2. Quantify changes in axonal integrity and organization in aMS versus naPMS patients over a two-year period. 3. Validate the combination of imaging parameters that best differentiate aMS versus naPMS patients using histopathology.

Eligibility

Age: 18 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria for patients:

* Patients may be diagnosed with:

  1. active RRMS (n=100): Relapsing-remitting course and \> 1 clinical relapse and/or signs of MRI activity (\> 1 Gd enhancing lesion) during the last year before study enrollment.
  2. non-active PMS (n=100): Progressive course (PPMS or SPMS) and no clinical relapses and/or signs of MRI activity during the last year before study enrollment.
* Age 18-80 years old
* No other neurological or psychiatric disorder

Inclusion criteria for healthy controls:

* Age 18-80 years old
* No other neurological or psychiatric disorder

Exclusion Criteria for patients and healthy controls:

* Pregnancy
* Contraindication to MRI (eg, claustrophobia, metallic implants, pacemaker etc).
* Inability to give consent

Conditions5

Multiple SclerosisMultiple Sclerosis (MS)Primary Progressive Multiple Sclerosis (PPMS)Relapsing-remitting Multiple Sclerosis (RRMS)Secondary Progressive Multiple Sclerosis (SPMS)

Browse More Trials

Multiple Sclerosis trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.